Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HHS Rebate Plan A Leap Of Faith? Lower Costs Hinge On Drug Firm, Plan Response

Executive Summary

HHS seeks input on how stakeholders might adjust to a system without rebates and requests comments on three actuarial reports that attempt to project the financial impact of the change.

Advertisement

Related Content

Invitation Accepted: Biopharma Leaders Will Testify At Senate Hearing On Pricing
Azar: International Regulatory Harmonization Will Create More Stable Generic Markets
The Rebate Effect: ‘Traditional’ Brand Costs Decline 6.5% In Commercial Plans
Azar: International Regulatory Harmonization Will Create More Stable Generic Markets
HHS Rebate Rule: At Least We Know Who Is In Charge
No More Rebates: HHS Proposed Rule Revises Anti-Kickback Safe Harbor
Pfizer Expects Rebate Reform By HHS Will Extend Quickly To Private Market

Topics

Advertisement
UsernamePublicRestriction

Register

PS124684

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel